1. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4872-8. doi: 
10.1016/j.bmcl.2006.06.061. Epub 2006 Jul 12.

Discovery of potent and stable conformationally constrained analogues of the MCH 
R1 antagonist SB-568849.

Witty DR(1), Bateson J, Hervieu GJ, Al-Barazanji K, Jeffrey P, Hamprecht D, 
Haynes A, Johnson CN, Muir AI, O'Hanlon PJ, Stemp G, Stevens AJ, Thewlis K, 
Winborn KY.

Author information:
(1)GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 
5AW, UK. david.witty@gsk.com

A strategy of systematically targeting more rigid analogues of the known MCH R1 
receptor antagonist, SB-568849, serendipitously uncovered a binding mode 
accessible to N-aryl-phthalimide ligands. Optimisation to improve the stability 
of this compound class led to the discovery of novel N-aryl-quinazolinones, 
benzotriazinones and thienopyrimidinones as selective ligands with good affinity 
for human melanin-concentrating hormone receptor 1.

DOI: 10.1016/j.bmcl.2006.06.061
PMID: 16839763 [Indexed for MEDLINE]
